346 related articles for article (PubMed ID: 33327450)
21. Bridging angiogenesis and immune evasion in the hypoxic tumor microenvironment.
Schito L
Am J Physiol Regul Integr Comp Physiol; 2018 Dec; 315(6):R1072-R1084. PubMed ID: 30183339
[TBL] [Abstract][Full Text] [Related]
22. Consequences of Extracellular Matrix Remodeling in Headway and Metastasis of Cancer along with Novel Immunotherapies: A Great Promise for Future Endeavor.
Ray SK; Mukherjee S
Anticancer Agents Med Chem; 2022; 22(7):1257-1271. PubMed ID: 34254930
[TBL] [Abstract][Full Text] [Related]
23. Potential Coagulation Factor-Driven Pro-Inflammatory Responses in Ovarian Cancer Tissues Associated with Insufficient O₂ and Plasma Supply.
Koizume S; Miyagi Y
Int J Mol Sci; 2017 Apr; 18(4):. PubMed ID: 28417928
[TBL] [Abstract][Full Text] [Related]
24. Tumor Hypoxia Regulates Immune Escape/Invasion: Influence on Angiogenesis and Potential Impact of Hypoxic Biomarkers on Cancer Therapies.
Abou Khouzam R; Brodaczewska K; Filipiak A; Zeinelabdin NA; Buart S; Szczylik C; Kieda C; Chouaib S
Front Immunol; 2020; 11():613114. PubMed ID: 33552076
[TBL] [Abstract][Full Text] [Related]
25. The role of vascular endothelial growth factor in the hypoxic and immunosuppressive tumor microenvironment: perspectives for therapeutic implications.
Tamura R; Tanaka T; Akasaki Y; Murayama Y; Yoshida K; Sasaki H
Med Oncol; 2019 Nov; 37(1):2. PubMed ID: 31713115
[TBL] [Abstract][Full Text] [Related]
26. Immunotherapy in Ovarian Cancer.
Wang W; Liu JR; Zou W
Surg Oncol Clin N Am; 2019 Jul; 28(3):447-464. PubMed ID: 31079799
[TBL] [Abstract][Full Text] [Related]
27. The hypoxic tumour microenvironment: A safe haven for immunosuppressive cells and a therapeutic barrier to overcome.
Chang WH; Lai AG
Cancer Lett; 2020 Sep; 487():34-44. PubMed ID: 32470490
[TBL] [Abstract][Full Text] [Related]
28. Engineering a Vascularized Hypoxic Tumor Model for Therapeutic Assessment.
Ando Y; Oh JM; Zhao W; Tran M; Shen K
Cells; 2021 Aug; 10(9):. PubMed ID: 34571851
[TBL] [Abstract][Full Text] [Related]
29. Combination therapy targeting both innate and adaptive immunity improves survival in a pre-clinical model of ovarian cancer.
Hartl CA; Bertschi A; Puerto RB; Andresen C; Cheney EM; Mittendorf EA; Guerriero JL; Goldberg MS
J Immunother Cancer; 2019 Jul; 7(1):199. PubMed ID: 31362778
[TBL] [Abstract][Full Text] [Related]
30. Losartan treatment enhances chemotherapy efficacy and reduces ascites in ovarian cancer models by normalizing the tumor stroma.
Zhao Y; Cao J; Melamed A; Worley M; Gockley A; Jones D; Nia HT; Zhang Y; Stylianopoulos T; Kumar AS; Mpekris F; Datta M; Sun Y; Wu L; Gao X; Yeku O; Del Carmen MG; Spriggs DR; Jain RK; Xu L
Proc Natl Acad Sci U S A; 2019 Feb; 116(6):2210-2219. PubMed ID: 30659155
[TBL] [Abstract][Full Text] [Related]
31. The Promise of Targeting Hypoxia to Improve Cancer Immunotherapy: Mirage or Reality?
Janji B; Chouaib S
Front Immunol; 2022; 13():880810. PubMed ID: 35795658
[TBL] [Abstract][Full Text] [Related]
32. CYR61, a potential biomarker of tumor inflammatory response in epithelial ovarian cancer microenvironment of tumor progress.
Shi J; Huo R; Li N; Li H; Zhai T; Li H; Shen B; Ye J; Fu R; Di W
BMC Cancer; 2019 Nov; 19(1):1140. PubMed ID: 31766991
[TBL] [Abstract][Full Text] [Related]
33. Hypoxia as a driver of resistance to immunotherapy.
Kopecka J; Salaroglio IC; Perez-Ruiz E; Sarmento-Ribeiro AB; Saponara S; De Las Rivas J; Riganti C
Drug Resist Updat; 2021 Dec; 59():100787. PubMed ID: 34840068
[TBL] [Abstract][Full Text] [Related]
34. Hypoxia as a potential inducer of immune tolerance, tumor plasticity and a driver of tumor mutational burden: Impact on cancer immunotherapy.
Abou Khouzam R; Janji B; Thiery J; Zaarour RF; Chamseddine AN; Mayr H; Savagner P; Kieda C; Gad S; Buart S; Lehn JM; Limani P; Chouaib S
Semin Cancer Biol; 2023 Dec; 97():104-123. PubMed ID: 38029865
[TBL] [Abstract][Full Text] [Related]
35. Immune Therapy Opportunities in Ovarian Cancer.
Kandalaft LE; Odunsi K; Coukos G
Am Soc Clin Oncol Educ Book; 2020 May; 40():1-13. PubMed ID: 32412818
[TBL] [Abstract][Full Text] [Related]
36. Anticoagulation therapy promotes the tumor immune-microenvironment and potentiates the efficacy of immunotherapy by alleviating hypoxia.
Choi JU; Lee NK; Seo H; Chung SW; Al-Hilal TA; Park SJ; Kweon S; Min N; Kim SK; Ahn S; Kim UI; Park JW; Kang CY; Kim IS; Kim SY; Kim K; Byun Y
J Immunother Cancer; 2021 Aug; 9(8):. PubMed ID: 34341129
[TBL] [Abstract][Full Text] [Related]
37. Combining Vascular Normalization with an Oncolytic Virus Enhances Immunotherapy in a Preclinical Model of Advanced-Stage Ovarian Cancer.
Matuszewska K; Santry LA; van Vloten JP; AuYeung AWK; Major PP; Lawler J; Wootton SK; Bridle BW; Petrik J
Clin Cancer Res; 2019 Mar; 25(5):1624-1638. PubMed ID: 30206160
[TBL] [Abstract][Full Text] [Related]
38. Mechanistic Justifications of Systemic Therapeutic Oxygenation of Tumors to Weaken the Hypoxia Inducible Factor 1α-Mediated Immunosuppression.
Hatfield S; Veszeleiova K; Steingold J; Sethuraman J; Sitkovsky M
Adv Exp Med Biol; 2019; 1136():113-121. PubMed ID: 31201720
[TBL] [Abstract][Full Text] [Related]
39. Improving Cancer Immunotherapy by Targeting the Hypoxic Tumor Microenvironment: New Opportunities and Challenges.
Noman MZ; Hasmim M; Lequeux A; Xiao M; Duhem C; Chouaib S; Berchem G; Janji B
Cells; 2019 Sep; 8(9):. PubMed ID: 31540045
[TBL] [Abstract][Full Text] [Related]
40. [Selected mechanisms inducing resistance to immunotherapy in patients with ovarian cancer].
Pietrzyk N; Piętak P; Pawłowska A; Suszczyk D; Chudzik A; Kotarski J; Wertel I
Wiad Lek; 2019; 72(7):1397-1402. PubMed ID: 31398175
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
